Core Insights - Obagi Medical has selected Schweiger Dermatology as a key partner for its Aesthetics Leadership with the Hyaluronic Acid (ALOHA) Program, emphasizing clinical excellence and rapid access to care [1] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare and aesthetic solutions, with over 35 years of experience in the industry [7] - Schweiger Dermatology is a prominent national dermatology practice that offers a range of services including medical, cosmetic, and surgical dermatology, focusing on high-quality, personalized care [8] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [9] Partnership Details - The partnership will generate real-world data to translate clinical safety and efficacy from FDA pivotal trials into everyday practice [2] - The ALOHA Program includes a Phase 4 clinical study and a real-world evaluation program to enhance patient satisfaction and provider-patient relationships [3] - Initial program activities are expected to commence in early 2026, with findings to be presented at internal leadership meetings and key industry conferences [4] Product Information - Obagi saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, aiming for natural-looking results and high performance [5]

NEW YORK and DALLAS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced It’s a Secret Med Spa as a key partner in the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. It’s a Secret Med Spa will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice ...

Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwideNEW YORK and IRVING, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Aesthetic Record as a key partner for the Aesthetics ...

Core Insights - DermFx has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on real-world data generation to validate the clinical safety and efficacy of Obagi's Hyaluronic Acid products in everyday practice [1][2] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5] - DermFx is a top-ranked medical spa in Southern California, specializing in advanced aesthetic treatments and has served tens of thousands of patients over 20+ years, emphasizing exceptional patient care and personalized protocols [6][7] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to provide DermFx with access to cutting-edge protocols and real-world insights, enhancing patient outcomes and allowing independent med spas to compete effectively [2][3] - The ALOHA Real-World Program will offer DermFx providers hands-on experience with Obagi saypha MagIQ™, utilizing proprietary technology for improved aesthetic results [3] Program Objectives - The ALOHA Program is designed to drive patient satisfaction and strengthen relationships between patients and DermFx providers through structured evaluations and standardized data capture [2] - Initial findings from the program will be presented at internal team meetings and regional events to highlight the benefits of the new protocols and products [2]

Core Insights - Next Health has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on personalized wellness and innovative aesthetic treatments [1] - The collaboration aims to conduct a structured assessment of Obagi's saypha MagIQ™ filler, leveraging Next Health's expertise in holistic protocols and patient-centric education [2] Company Overview - Obagi Medical is recognized for its advanced skincare solutions, with over 35 years of experience, and is the fastest-growing professional skincare brand in the U.S. as of 2024 [6][10] - Next Health, founded in 2016, specializes in health optimization and longevity, offering services like IV therapy and hormone optimization through a network of wellness centers [7] Program Details - The ALOHA Program evaluates clinical efficacy and patient experience, aiming to enhance satisfaction and loyalty through integrated Obagi protocols [3] - Standardized data will be collected across Next Health locations, with initial findings to be shared at leadership meetings and major industry conferences [3] Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi saypha MagIQ™ across Alpha's network, focusing on generating real-world evidence of the product's integration into clinical environments [2][3] - The program aims to assess both clinical performance and patient experience, with standardized data collection across participating practices, and initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi saypha ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, designed for natural-looking results and high performance [4]

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the launch partner for its ALOHA Program, focusing on the integration of clinical evidence into everyday practice [1][2] Company Overview - Obagi Medical is recognized for its innovative physician-dispensed skincare solutions and has over 35 years of experience in the industry, particularly in treating skin concerns like hyperpigmentation and premature aging [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, emphasizing a collaborative practice model to enhance patient care [7] Program Details - The ALOHA Program aims to generate real-world data to validate the safety and efficacy of Obagi's products, specifically the saypha MagIQ injectable, through hands-on experience and structured evaluations [2][3] - Initial findings from the ALOHA Program will be presented at the annual Platinum Summit in September, showcasing the benefits of the new product within the Platinum network [4] Strategic Intent - The partnership with Platinum signifies Obagi's commitment to launching new injectables based on robust clinical evidence and integrated patient outcomes, aligning with the company's innovative approach to product development [5]

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the first partner for its ALOHA Program, emphasizing a commitment to clinical evidence and practice dissemination [1][5] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare and aesthetic solutions, part of Waldencast plc, with over 35 years of experience in advanced skincare [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, focusing on exceptional dermatology practices [7] - Waldencast plc aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to generate real-world data to translate clinical safety and efficacy from FDA trials into everyday practice [2] - The ALOHA Real-World Program will provide hands-on experience with Obagi saypha MagIQ, enhancing patient satisfaction and provider relationships [3] - Initial findings from the program will be presented at the annual Platinum Summit and key industry conferences to showcase the product's real-world impact [4] Product Information - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed for natural-looking results and high performance [5]

Core Insights - Obagi Medical has launched the ALOHA Program aimed at driving innovation in aesthetic practices through real-world evidence and insights [1][2] - The program will support the introduction of Obagi saypha MagIQ™, the first FDA-approved injectable hyaluronic acid filler from the company, featuring high usable HA content and a predictable injection profile [1][2] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare with over 35 years of experience, initially known for its Obagi Nu-Derm System targeting hyperpigmentation [3] - The company is the fastest-growing professional skincare brand in the U.S. as of 2024, focusing on various skin concerns including aging, photodamage, and acne [3] Program Details - The ALOHA Program will gather real-world data from diverse practice settings to demonstrate the effectiveness of Obagi saypha MagIQ™ and its skincare products in enhancing practice success and patient satisfaction [2] - Participants in the program will provide structured feedback through standardized surveys, creating a comprehensive evaluation of the new HA injectable beyond traditional clinical trials [2] Industry Context - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, ensuring agility and market responsiveness [4] - The company's strategy includes leveraging operational scale and expertise in managing beauty brands to mitigate category fluctuations and enhance brand performance [4]

Core Insights - Waldencast plc has received FDA approval for Obagi saypha MagIQ™ injectable hyaluronic acid gel, marking its entry into the U.S. HA dermal filler market and aiming to double Obagi Medical's addressable market to approximately $4.2 billion by 2029 [1][2] Company Overview - Waldencast aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, with a focus on operational scale and market responsiveness [8] - Obagi Medical is recognized for its advanced skincare line with over 35 years of experience, initially known for treating hyperpigmentation [9] - Croma-Pharma GmbH, a partner in developing Obagi saypha MagIQ™, has over 40 years of expertise in HA-based treatments and has produced more than 110 million syringes [4][10] Product Details - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix, providing natural-looking results with high HA content and consistent gel distribution [3] - The product is expected to set a new standard in HA dermal fillers in the U.S., with a strong safety profile and proven innovation [2][5] Market Strategy - The launch of Obagi saypha MagIQ™ is planned for 2026, leveraging Obagi Medical's established network of practices and aesthetic professionals to enhance value for providers and patients [2][5] - The U.S. Nasolabial Fold pivotal study for Obagi saypha MagIQ™ included 270 patients and demonstrated non-inferiority to the control with similar safety profiles [5][6]